Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1Breast 1

Conditions

Tuberous Sclerosis 4Seizures 3Lennox Gastaut Syndrome 3Epilepsies, Myoclonic 3Anxiety Disorders 2Tuberous Sclerosis 2 1Tuberous Sclerosis 1 1Spasms, Infantile 1Prostatic Neoplasms 1Parasomnias 1Pain 1Neoplasms 1Nausea 1Marijuana Abuse 1Liver Cirrhosis 1Glioblastoma 1Epilepsy 1Colorectal Neoplasms 1Colonic Neoplasms 1Chemotherapy-Induced Peripheral Neuropathy 1Carcinoma, Intraductal, Noninfiltrating 1Cancer Pain 1Breast Neoplasms 1Breast Carcinoma In Situ 1Behavior 1

Interventions

Fulvestrant 127Trastuzumab 117Paclitaxel 113Letrozole 109pembrolizumab 81palbociclib 76pertuzumab 75Capecitabine 74Anastrozole 72Cyclophosphamide 70Carboplatin 67abemaciclib 65exemestane 63Tamoxifen 63ribociclib 61trastuzumab deruxtecan 57Specimen Handling 51Surveys and Questionnaires 50Radiotherapy 50Docetaxel 49Magnetic Resonance Spectroscopy 48Blood Specimen Collection 42olaparib 40Standard of Care 36Biopsy 33sacituzumab govitecan 32130-nm albumin-bound paclitaxel 32Exercise 30Doxorubicin 30eribulin 29

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Breast Neoplasms × Cannabidiol × 1 year × Clear all
NCT06731894 2025-12-05

Phytocannabinoids for Reducing Chronic Chemotherapy-Induced Peripheral Neuropathy in Breast and Colon Cancer Survivors

City of Hope Medical Center

Phase 2 Recruiting
120 enrolled
BreastGastrointestinal

Breast Neoplasms, Colonic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡